Reshma A. Patel
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Peptidase Inhibition and Analysis, Neuropeptides and Animal Physiology, Diabetes Treatment and Management, Chemical Synthesis and Analysis, Synthesis and Biological Evaluation
Most-Cited Works
- → (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2004)814 cited
- → Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes(2005)490 cited
- → Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII(2003)181 cited
- → (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2006)121 cited
- → Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors(2008)106 cited
- → Substituted piperazines as novel dipeptidyl peptidase IV inhibitors(2004)97 cited
- → Discovery of potent and selective β-homophenylalanine based dipeptidyl peptidase IV inhibitors(2004)76 cited
- → Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors(2005)68 cited
- → Dipeptidyl peptidase IV inhibitors derived from β-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole(2005)63 cited
- → Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: Close analogs of JANUVIA™ (sitagliptin phosphate)(2007)58 cited